Supplementary References

31sMusher DM. Neurosyphilis: diagnosis and response to treatment. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2008;47(7):900-902.

32s. Marra CM, Tantalo LC, Sahi SK, et al. CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis. *Sexually transmitted diseases.* 2010;37(5):283-287.

33s. Marra CM, Maxwell CL, Dunaway SB, et al. Cerebrospinal Fluid Treponema pallidum Particle Agglutination Assay for Neurosyphilis Diagnosis. *Journal of clinical microbiology.* 2017;55(6):1865-1870.

34s. Harding AS, Ghanem KG. The performance of cerebrospinal fluid treponemal-specific antibody tests in neurosyphilis: a systematic review. *Sexually transmitted diseases.* 2012;39(4):291-297.

35s. Guarner J, Jost H, Pillay A, et al. Evaluation of treponemal serum tests performed on cerebrospinal fluid for diagnosis of neurosyphilis. *American journal of clinical pathology.* 2015;143(4):479-484.

36s. Ho EL, Tantalo LC, Jones T, et al. Point-of-care treponemal tests for neurosyphilis diagnosis. *Sexually transmitted diseases.* 2015;42(1):48-52.

37s. Ho EL, Marra CM. Treponemal tests for neurosyphilis--less accurate than what we thought? *Sexually transmitted diseases.* 2012;39(4):298-299.

38s. Marra CM, Critchlow CW, Hook EW, 3rd, et al. Cerebrospinal fluid treponemal antibodies in untreated early syphilis. *Archives of neurology.* 1995;52(1):68-72.

39s. Jurado R, Walker HK. Cerebrospinal Fluid. In: Walker HK, Hall WD, Hurst JW, eds. *Clinical Methods: The History, Physical, and Laboratory Examinations*. 3rd ed. Boston1990.

40s. Marra CM, Maxwell CL, Collier AC, et al. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. *BMC infectious diseases.* 2007;7:37.

41s. Marra CM, Maxwell CL, Tantalo L, et al. Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter? *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2004;38(7):1001-1006.

42s. Lin LR, Lin DH, Tong ML, et al. Macrophage migration inhibitory factor as a novel cerebrospinal fluid marker for neurosyphilis among HIV-negative patients. *Clinica chimica acta; international journal of clinical chemistry.* 2016;463:103-108.

43s. Wang C, Wu K, Yu Q, et al. CXCL13, CXCL10 and CXCL8 as Potential Biomarkers for the Diagnosis of Neurosyphilis Patients. *Scientific reports.* 2016;6:33569.

44s. Mothapo KM, Verbeek MM, van der Velden LB, et al. Has CXCL13 an added value in diagnosis of neurosyphilis? *Journal of clinical microbiology.* 2015;53(5):1693-1696.

45s. Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. *The New England journal of medicine.* 1997;337(5):307-314.

46s. Hopkins H. Prognostic import of a negative spinal fluid in early and in latent syphilis. *Archives of dermatology and syphilology.* 1931;24:404-408.

47s. Bayne LL, Schmidley JW, Goodin DS. Acute syphilitic meningitis. Its occurrence after clinical and serologic cure of secondary syphilis with penicillin G. *Archives of neurology.* 1986;43(2):137-138.

48s. Berger JR. Neurosyphilis in human immunodeficiency virus type 1-seropositive individuals. A prospective study. *Archives of neurology.* 1991;48(7):700-702.

49s. Berry CD, Hooton TM, Collier AC, et al. Neurologic relapse after benzathine penicillin therapy for secondary syphilis in a patient with HIV infection. *The New England journal of medicine.* 1987;316(25):1587-1589.

50s. Ghanem KG, Moore RD, Rompalo AM, et al. Lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2009;48(6):816-821.

51s. Marra CM, Maxwell CL, Smith SL, et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. *The Journal of infectious diseases.* 2004;189(3):369-376.

52s. Ganesan A, Mesner O, Okulicz JF, et al. A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2015;60(4):653-660.

53s. Yang CJ, Lee NY, Chen TC, et al. One dose versus three weekly doses of benzathine penicillin G for patients co-infected with HIV and early syphilis: a multicenter, prospective observational study. *PloS one.* 2014;9(10):e109667.

54s. Tomkins A, Ahmad S, Cousins DE, et al. Screening for asymptomatic neurosyphilis in HIV patients after treatment of early syphilis: an observational study. *Sexually transmitted infections.* 2017.

55s. Clement ME, Okeke NL, Hicks CB. Treatment of syphilis: a systematic review. *Jama.* 2014;312(18):1905-1917.

56s. Zhou P, Gu X, Lu H, et al. Re-evaluation of serological criteria for early syphilis treatment efficacy: progression to neurosyphilis despite therapy. *Sexually transmitted infections.* 2012;88(5):342-345.

57s. Ren RX, Wang LN, Zheng HY, et al. No improvement in serological response among serofast latent patients retreated with benzathine penicillin. *International journal of STD & AIDS.* 2016;27(1):58-62.

58s. Sena AC, Wolff M, Behets F, et al. Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2013;56(3):420-422.

59s. Shann S, Wilson J. Treatment of neurosyphilis with ceftriaxone. *Sexually transmitted infections.* 2003;79(5):415-416.

60s. Marra CM, Boutin P, McArthur JC, et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus-infected individuals. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2000;30(3):540-544.

61s. Gentile JH, Viviani C, Sparo MD, et al. Syphilitic meningomyelitis treated with ceftriaxone: case report. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 1998;26(2):528.

62s. Centers for Disease C. Sexually transmitted diseases treatment guidelines 1982. *MMWR. Morbidity and mortality weekly report.* 1982;31 Suppl 2:33S-60S.

63s. Mohr JA, Griffiths W, Jackson R, et al. Neurosyphilis and penicillin levels in cerebrospinal fluid. *Jama.* 1976;236(19):2208-2209.

64s. Short DH, Knox JM, Glicksman J. Neurosyphilis, the search for adequate treatment. A review and report of a study using benzathine penicillin G. *Archives of dermatology.* 1966;93(1):87-91.